ADRB3 and nonpapillary renal cell carcinoma: To explore the dual impact of β3-AR agonists on fat metabolism and immune modulation in a relevant disease model, we focused on ccRCC, which exhibits both adipose involvement and immune responsiveness [15, 16, 17].